Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...
On schedule, Biomarin Pharmaceutical Inc. this week finished off the rolling new drug application (NDA) for exon 51-skipping drisapersen to treat Duchenne muscular dystrophy (DMD), situating the firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results